Baviera et al. conducted a cohort study (1) which mainly focused on the effectiveness of glucagon-like peptide 1 receptor agonists (GLP1RAs) vs. sodium-glucose cotransporter 2 inhibitors (SGLT2is) on cardiovascular and cerebrovascular endpoints in patients with type 2 diabetes (T2D). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.